When was AN2 Therapeutics founded?

AN2 Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is AN2 Therapeutics located?

AN2 Therapeutics is headquartered in Menlo Park, United States.

Who is the current CEO of AN2 Therapeutics?

Eric Easom of AN2 Therapeutics. They have also founded 1 company.

How many employees does AN2 Therapeutics have?

As of Aug 31, 2026, the latest employee count at AN2 Therapeutics is 39.

Is AN2 Therapeutics a funded company?

AN2 Therapeutics is a funded company, having raised a total of $92M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 21, 2019.

When was the latest funding round of AN2 Therapeutics?

AN2 Therapeutics' latest funding was a $***** Post IPO round on Mar 09, 2026, with participation from 3 investors.

Where does AN2 Therapeutics rank among its competitors?

AN2 Therapeutics ranks 142nd amongst 2704 active competitors, of which 892 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of AN2 Therapeutics?

AN2 Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

AN2 Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of drugs for treating infectious disease. The company is developing novel small molecule therapeutics, designing and executing clinical trials on experimental treatments, and navigating the regulatory approval process for new medicines.

Key Metrics

Founded Year

2017

Location

Menlo Park, United States

Stage

Public

Total Funding

$92M in 3 rounds

Latest Funding Round

Post IPO, Mar 09, 2026, $*****

Investors

RA Capital Management & 14 more

Ranked

142^nd among 2704 active competitors

Employee Count

39 as on Aug 31, 2026

Similar Companies

Moderna & 363 more

Exit Details

Public

View AN2 Therapeutics' full profile

AN2 Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AN2 THERAPEUTICS, INC. CIN: 1880438 , United States, Active	Feb 23, 2017	-	35 (As on Feb 28, 2023)	-

AN2 Therapeutics got listed on Mar 25, 2022.

Click here to take a look at AN2 Therapeutics's IPO in detail

AN2 Therapeutics has raised a total funding of $92M over 3 rounds. Its first funding round was on Nov 21, 2019. Its latest funding round was a Post IPO round on Mar 09, 2026 for $*****. 3 investors participated in its latest round. AN2 Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of AN2 Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 09, 2026	4457817	Post IPO	4240377	5216174	7036153	6662857
Jan 07, 2022	6296843	Series B	2489417	3575874	8747185	BVF Partners & 4 more
Nov 21, 2019	1051708	Series A	3754015	7340872	Mountain Group Partners	Adjuvant Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of AN2 Therapeutics's funding rounds and investors

The founders of AN2 Therapeutics are Eric Easom and Michael R.K Alley. Eric Easom is the CEO of AN2 Therapeutics.

Here are the details of AN2 Therapeutics' key team members:

Eric Easom: Co-Founder & CEO & President of AN2 Therapeutics.
Contact Info: 1 email address
Michael R.K Alley: Co-Founder of AN2 Therapeutics.
Contact Info: 1 email address

View details of AN2 Therapeutics's Founder profiles and Board Members

AN2 Therapeutics' employee count trend

AN2 Therapeutics has 39 employees as of Aug 26. Here is AN2 Therapeutics's employee count trend over the years:

Employee count trend for AN2 Therapeutics

Uncover AN2 Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AN2 Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of AN2 Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
142nd	AN2 Therapeutics 2017, Menlo Park (United States), Public	Developer of drugs for treating infectious disease	$92M	BVF Partners, RA Capital Management & 13 others	60/100